Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BI 1569912 on Pharmacokinetics of Repaglinide, Midazolam and Bupropion in Healthy Subjects
NCT06367153Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 1569912, sponsored by Boehringer Ingelheim. Primary endpoint: Area Under the Concentration-time Curve from 0 Extrapolated to Infinity at 12 hours. Started May 2024; status: completed.
02
Drugs
BI 1569912
Beyond the preview
Go deeper on NCT06367153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06367153.